Masatake Matsuoka

Dr. Masatake Matsuoka

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
MOMasanori Okamoto
Masanori Okamoto
MMMasatake Matsuoka
Masatake Matsuoka
TSTamotsu Soma
Tamotsu Soma
RARyuta Arai
Ryuta Arai
HKHidenori Kato
Hidenori Kato
HHHiroaki Hiraga
Hiroaki Hiraga
Background: Hepatic metastasis of soft tissue sarcoma is rare compared to lung metastasis, and the literature is scarce. We examined the risk of hepatic metastasis according to the site of occurrence and histological type.Methods: From a Hospital‐based Cancer Registry, 658 patients registered between 2007 and 2017 with soft tissue sarcomas were evaluated. The exclusion criteria were gastrointestinal stromal tumors, tumors of unknown origin, and follow‐up periods of less than 1 month. SPSS 25 was used for statistical analysis.Results: The risk of hepatic metastasis was significantly higher in the retroperitoneum (HR, 5.981; 95% CI, 2.793‐12.808) and leiomyosarcoma (HR, 4.303; 95% CI, 1.782‐10.390). Multivariate analysis showed that the risk of hepatic metastasis as first distant metastasis was high in leiomyosarcoma (HR, 4.546; 95% CI, 2.275‐9.086) and retroperitoneal onset (HR, 4.588; 95% CI, 2.280‐9.231). The 2‐year survival rate after hepatic metastasis was 21.7%.Conclusions: The onset of hepatic metastasis indicates a poor prognosis. However, hepatic metastasis from retroperitoneal sarcoma and leiomyosarcoma may be the first distant metastasis in some cases. For retroperitoneal sarcoma and leiomyosarcoma, additional screening for hepatic metastasis such as contrast CT should be considered during staging and follow‐up after treatment.

1 June 2021 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
MMMasatake Matsuoka
Masatake Matsuoka
TOT. Onodera
T. Onodera
IYI. Yokota
I. Yokota
KIK. Iwasaki
K. Iwasaki
SMS. Matsubara
S. Matsubara
NIN. Iwasaki
N. Iwasaki

3 November 2021 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
RIRyo Itoga
Ryo Itoga
MMMasatake Matsuoka
Masatake Matsuoka
TOTomohiro Onodera
Tomohiro Onodera
IYIsao Yokota
Isao Yokota
KIKoji Iwasaki
Koji Iwasaki
NINorimasa Iwasaki
Norimasa Iwasaki
Background/Aim: Brain metastasis is a rare condition among patients with soft tissue sarcoma (STS), and its precise incidence remains unclear. The aim of this study was to investigate which patients should be screened for brain metastasis. Patients and Methods: We identified all patients with STS diagnosed between 2010 and 2015 in the SEER database. Incidence of brain metastasis at initial presentation and higher incidence of brain metastasis by histological subtype were investigated. In addition, risk factors for brain metastasis were examined. Results: A total of 26,676 patients were included for analysis, of whom 162 patients (0.6%) had brain metastasis. Alveolar soft part sarcoma (6.3%), malignant hemangioendothelioma (3.1%) and malignant schwannoma (2.6%) showed higher incidence of brain metastasis. Deep-rooted tumor, trunk tumor, and histological high-grade tumor tended to show higher incidence of brain metastasis. Conclusion: Risk factors for brain metastasis were deep location, trunk development and histologically high-grade tumor, or specific histological subtypes.

9 January 2023 in Journal of Orthopaedic Science
Verified
Journal Article
Closed access
TKTakuma Kaibara
Takuma Kaibara
EKEiji Kondo
Eiji Kondo
MMMasatake Matsuoka
Masatake Matsuoka
KIKoji Iwasaki
Koji Iwasaki
TOTomohiro Onodera
Tomohiro Onodera
NINorimasa Iwasaki
Norimasa Iwasaki

15 March 2023 in Journal of Orthopaedic Science
Verified
Journal Article
Closed access
MMMasatake Matsuoka
Masatake Matsuoka
TOTomohiro Onodera
Tomohiro Onodera
IYIsao Yokota
Isao Yokota
KIKoji Iwasaki
Koji Iwasaki
RHRyosuke Hishimura
Ryosuke Hishimura
NINorimasa Iwasaki
Norimasa Iwasaki

30 July 2020 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
TKTakuma Kaibara
Takuma Kaibara
EKEiji Kondo
Eiji Kondo
MMMasatake Matsuoka
Masatake Matsuoka
KIKoji Iwasaki
Koji Iwasaki
TOTomohiro Onodera
Tomohiro Onodera
NINorimasa Iwasaki
Norimasa Iwasaki
Background: Articular surface damage commonly associated with rupture of the anterior cruciate ligament (ACL). Large osteochondral defect, which consists of a severe depression fracture and a large cartilage defect, need to be treated due to deformation of the articular surface as it can impact the clinical outcome of ACL reconstruction. Although autologous chondrocyte implantation is one of the useful options in such cases, it can be questioned whether the reconstruction of the ACL and osteochondral defect should be performed in one procedure alone.Case presentation: We report a case of a 38-year-old male with a deep depression fracture extending to the edge of the lateral femoral condyle associated with ACL injury after twisting his right knee while skiing. The patient was successfully treated with tissue-engineered cartilage transplantation covered by the periosteum with an iliac bone graft combined with anatomic double-bundle ACL reconstruction. Histopathological examination of the transplanted cartilage taken at second-look arthroscopy showed a cartilage-like tissue in the middle to deep zone in which the extracellular matrix was largely stained with Safranin O. The patient was able to return to his previous level of skiing activity without any experience of knee pain. Magnetic resonance imaging at 4 years after surgery showed that the graft integrated to the border zone and subchondral bone. The operated knee showed negative Lachman test and had a full range of motion.Conclusions: To our knowledge, this is the first report of anatomic double-bundle ACL reconstruction with tissue-engineered cartilage transplantation and an iliac bone graft to restore the lateral edge of the femoral condyle.